{"id":"phenglutarimide","rwe":[],"tags":[{"label":"phenglutarimide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N04AA09","category":"atc"},{"label":"Active","category":"status"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"phenglutarimid","offLabel":[],"synonyms":["phenglutarimide hydrochloride","phenglutarimide HCl","phenylglutarimide","phenglutarimide","phenglutarimid"],"timeline":[],"approvals":[],"brandName":"Phenglutarimid","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"phenglutarimide","explanation":"Imagine your body's cells are like locks, and phenglutarimide is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, or change how it works. But since we don't know what lock it's meant to fit into, we can't be sure how it will affect the body.","oneSentence":"Phenglutarimide is thought to work by interacting with a specific biological target, but its exact mechanism is not yet understood.","technicalDetail":"Phenglutarimide's mechanism of action is currently unknown, and further research is needed to elucidate its target and pharmacological effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2127","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PHENGLUTARIMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:18:13.423905","biosimilars":[],"competitors":[{"drugName":"trihexyphenidyl","drugSlug":"trihexyphenidyl","fdaApproval":"1949-05-13","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"biperiden","drugSlug":"biperiden","fdaApproval":"1959-09-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"metixene","drugSlug":"metixene","fdaApproval":"","relationship":"same-class"},{"drugName":"procyclidine","drugSlug":"procyclidine","fdaApproval":"1955-07-27","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"profenamine","drugSlug":"profenamine","fdaApproval":"","relationship":"same-class"}],"genericName":"phenglutarimide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"trihexyphenidyl","brandName":"trihexyphenidyl","genericName":"trihexyphenidyl","approvalYear":"1949","relationship":"same-class"},{"drugId":"biperiden","brandName":"biperiden","genericName":"biperiden","approvalYear":"1959","relationship":"same-class"},{"drugId":"metixene","brandName":"metixene","genericName":"metixene","approvalYear":"","relationship":"same-class"},{"drugId":"procyclidine","brandName":"procyclidine","genericName":"procyclidine","approvalYear":"1955","relationship":"same-class"},{"drugId":"profenamine","brandName":"profenamine","genericName":"profenamine","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"679RC9H8TG","CHEBI":"CHEBI:135195","INN_ID":"921","UMLSCUI":"C0070561","ChEMBL_ID":"CHEMBL1096643","KEGG_DRUG":"D07301","DRUGBANK_ID":"DB13413","PUBCHEM_CID":"102669","SECONDARY_CAS_RN":"1674-96-0","MESH_SUPPLEMENTAL_RECORD_UI":"C005440"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":8,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"N04AA09","allCodes":["N04AA09"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Phenglutarimide is a small molecule drug of the phenglutarimide class, but its target and mechanism of action are unknown. Its commercial status and approved indications are also unclear. As a result, key safety considerations and pharmacokinetic properties such as half-life and bioavailability are not well established. Further research is needed to fully understand this compound. Its current owner and development history are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}